Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
CanadaIPO:
12 October 1995Next earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 17:49:51 GMTDividend
Analysts recommendations
Institutional Ownership
ACHV Latest News
Achieve Life Sciences is working to commercialize the smoking cessation drug Cytisinicline, which has shown promising results in clinical trials. The drug has a superior safety profile compared to existing treatment options and has the potential to address a large market. The company is expected to be sold to a larger entity in 2025, with potential returns of 4-9x for investors.
Achieve Life Sciences, Inc. (ACHV) Q4 2023 Earnings Call Transcript
Achieve Life Sciences (NASDAQ: ACHV ) stock is dropping on Tuesday after the company provided an update on its New Drug Application (NDA) for cytisinicline. A meeting with the Food and Drug Administration (FDA) saw the agency request additional data concerning cytisinicline before it will approve its NDA.
SEATTLE and VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will be participating in the following upcoming investor conferences.
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Nicole Jones - IR John Bencich - CEO Jerry Wan - Principal Accounting Officer Cindy Jacobs - President and CMO Conference Call Participants Thomas Flaten - Lake Street Michael Higgins - Ladenburg Thalmann John Vandermosten - Saks Operator Greetings. Welcome to Achieve Life Sciences Third Quarter Earnings Conference Call and Webcast.
Efficacy: Phase 3 ORCA-3 trial showed significant efficacy of cytisinicline in smoking cessation, reinforcing data from ORCA-2. Safety: Cytisinicline exhibited no serious treatment-related adverse events, implying safe long-term usage.
Achieve Life Sciences Inc. ACHV, +12.88% said Tuesday a second confirmatory late-stage trial of its cytisinicline for quitting smoking and nicotine dependence achieved positive results, showing a statistically significant benefit compared to placebo. The Phase 3 trial involved 792 adult smokers at 20 trial sites in the U.S. who were dosed 3 times daily with 3mg of cytisinicline for a period of six weeks or 12 weeks.
What type of business is Achieve Life Sciences?
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
What sector is Achieve Life Sciences in?
Achieve Life Sciences is in the Healthcare sector
What industry is Achieve Life Sciences in?
Achieve Life Sciences is in the Biotechnology industry
What country is Achieve Life Sciences from?
Achieve Life Sciences is headquartered in Canada
When did Achieve Life Sciences go public?
Achieve Life Sciences initial public offering (IPO) was on 12 October 1995
What is Achieve Life Sciences website?
https://www.achievelifesciences.com
Is Achieve Life Sciences in the S&P 500?
No, Achieve Life Sciences is not included in the S&P 500 index
Is Achieve Life Sciences in the NASDAQ 100?
No, Achieve Life Sciences is not included in the NASDAQ 100 index
Is Achieve Life Sciences in the Dow Jones?
No, Achieve Life Sciences is not included in the Dow Jones index
When does Achieve Life Sciences report earnings?
The next expected earnings date for Achieve Life Sciences is 14 August 2024